Insights from the RedirecTT-1 Study: A Potential Game-Changer for R/R Myeloma with EMD

Shahzad Raza, MD, Hematologist at Cleveland Clinic, joins the Cancer Advances podcast to share insights from the RedirecTT-1 study. This study, presented at the 2025 American Society of Hematology (ASH) Annual Meeting, explores combining two bispecific antibodies, talquetamab and teclistamab, for patients with relapsed/refractory multiple myeloma with extramedullary disease. Listen as Dr. Raza discusses disease biology, outcomes, safety considerations and why this approach could be a major step forward for high-risk myeloma care.